
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
As a pediatric resident, I am comfortably situated under the umbrella of academic medicine, where I make my choices and bounce them off people who've already trodden these paths. I hear their experiential biases and incorporate them into my evaluation of patients.






